36 research outputs found
MOBILITY AND BIOAVAILABILITY OF HEAVY METALS AND METALLOIDS IN SOIL ENVIRONMENTS
In soil environments, sorption/desorption reactions as well as chemical complexation with inorganic and organic ligands and redox reactions, both biotic and abiotic, are of great importance in controlling their bioavailability, leaching and toxicity. These reactions are affected by many factors such as pH, nature of the sorbents, presence and concentration of organic and inorganic ligands, including humic and fulvic acid, root exudates, microbial metabolites and nutrients. In this review, we highlight the impact of physical, chemical, and biological interfacial interactions on bioavailability and mobility of metals and metalloids in soil. Special attention is devoted to: i) the sorption/desorption processes of metals and metalloids on/from soil components and soils; ii) their precipitation and reduction-oxidation reactions in solution and onto surfaces of soil components; iii) their chemical speciation, fractionation and bioavailability
Corrections to the generalized vector dominance due to diffractive rho_3 production
The idea of the vector dominance is still in use in various analyses of
experimental data of photon-hadron reactions. It makes sense, therefore, to
recast results of microscopic calculations of such reactions in this language.
Here we present the diffractive DIS production as a specific
correction to the generalized vector dominance. We perform a coupled channel
analysis of spin-orbital excitations in diffractive photoproduction and
reiterate the point that rho_3 in diffractive DIS will be sensitive to a novel
aspect of diffraction.Comment: 12 pages, 2 figure
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
Background: Platinum/fluoropyrimidine regimens are the backbone of first-line chemotherapy for advanced gastric
cancer (AGC). However response rates to first line chemotherapy range from 30 to 50% and disease progression
occurs after 4\u20136 cycles. The optimal duration of first-line therapy is still unknown and its continuation until disease
progression represents the standard. However this strategy is often associated with cumulative toxicity and rapid
development of drug resistance. Moreover, only about 40% of AGC pts. are eligible for second-line treatment.
Methods: This is a randomized, open-label, multicenter phase III trial. It aims at assessing whether switch
maintenance to ramucirumab plus paclitaxel will extend the progression-free survival (PFS) of subjects with
HER-2 negative AGC who have not progressed after 3 months of a first-line with a platinum/fluoropyrimidine
regimen (either FOLFOX4, mFOLFOX6 or XELOX). The primary endpoint is to compare Progression-Free
Survival (PFS) of patients in ARM A (switch maintenance to ramucirumab and placlitaxel) versus ARM B
(continuation of the same first-line therapy with oxaliplatin/fluoropyrimidine). Secondary endpoints are: overall
survival, time-to-treatment failure, overall response rate, duration of response, percentage of patients that will
receive a second line therapy according to arm treatment, safety, quality of life. Exploratory studies including
Next-Generation Sequencing (NGS) in archival tumor tissues are planned in order to identify potential biomarkers of
primary resistance and prognosis.
(Continued on next page)
Discussion: The ARMANI study estimates if patients treated with early swich with ramucirumab plus paclitaxel received
benefit when compared to those treated with continuation of first line therapy. The hypothesis is that the
early administration of an active, non-cross resistant second-line regimen such as ramucirumab plus paclitaxel
may prolong the time in which patients are progression-free, and consequently have a better quality of life.
Moreover, this strategy may rescue all those subjects that become ineligible for second-line therapy due to
the rapid deterioration of health status after the first disease progression.
Trial registration: ARMANI is registered at ClinicalTrials.gov (NCT02934464, October 17, 2016) and
EudraCT(2016\u2013001783-12, April 202,016)
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.
BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362